Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bonkhoff, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonkhoff, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S141-S144, 2001
© 2001 European Society for Medical Oncology

Reviews

Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status

H. Bonkhoff

Institute of Pathology, University of the Saarland 66421 Homburg/Saar Germany

Correspondence to: H. Bonkhoff, MD Institute of Pathology University of the Saarland 66421 Homburg/Saar Germany E-mail: pahbon{at}med-rz.uni-sb.de

Background: The frequent occurrence of neuroendocrine (NE) differentiation in common prostatic malignancies has attracted increasing attention in contemporary prostate cancer research.

Methods: The present review focuses on growth properties and the androgen receptor (AR) status of NE phenotypes, and discusses their morphogenetic origin in benign and malignant prostate tissue.

Results: Recent data have documented a phenotype link between NE cells and other cell lineages encountered in benign and malignant prostate tissue. NE tumor cells (as defined by the most commonly used endocrine marker chromogranin A) do not proliferate or show apoptotic activity. This particular phenotype also lacks the nuclear AR in both benign and malignant conditions.

Conclusions: Prostatic NE cells most likely derive from local stem cells and represent terminally differentiated and androgen-insensitive cell populations in benign prostate tissue. The frequent occurrence of NE differentiation in prostatic adenocarcinoma obviously reflects the differentiation repertoire of its stem cells. Neoplastic NE cells devoid of nuclear AR constitute an androgen-insensitive cell population in prostate cancer. The absence of proliferative and apoptotic activity may endow NE tumor cells with relative resistance towards cytotoxic drugs and radiation therapy.

androgen receptor, morphogenesis, neuroendocrine differentiation, proliferation, prostate cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. J. Mulholland, L. Xin, A. Morim, D. Lawson, O. Witte, and H. Wu
Lin-Sca-1+CD49fhigh Stem/Progenitors Are Tumor-Initiating Cells in the Pten-Null Prostate Cancer Model
Cancer Res., November 15, 2009; 69(22): 8555 - 8562.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Deng, H. Liu, J. Huang, L. Cheng, E. T. Keller, S. J. Parsons, and C.-D. Hu
Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression
Cancer Res., December 1, 2008; 68(23): 9663 - 9670.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Camoriano, S. R. Morey Kinney, M. T. Moser, B. A. Foster, J. L. Mohler, D. L. Trump, A. R. Karpf, and D. J. Smiraglia
Phenotype-Specific CpG Island Methylation Events in a Murine Model of Prostate Cancer
Cancer Res., June 1, 2008; 68(11): 4173 - 4182.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zhou, A. Flesken-Nikitin, and A. Yu. Nikitin
Prostate Cancer Associated with p53 and Rb Deficiency Arises from the Stem/Progenitor Cell-Enriched Proximal Region of Prostatic Ducts
Cancer Res., June 15, 2007; 67(12): 5683 - 5690.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zhou, A. Flesken-Nikitin, D. C. Corney, W. Wang, D. W. Goodrich, P. Roy-Burman, and A. Yu. Nikitin
Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer
Cancer Res., August 15, 2006; 66(16): 7889 - 7898.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al.
Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland
J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.